Article
Phase 1 Study of Rezatapopt, a p53 Reactivator, in TP53 Y220C-Mutated Tumors.
The New England journal of medicine - 26 Feb 2026
Dumbrava Ecaterina E, Shapiro Geoffrey I, Parikh Aparna R, Johnson Melissa L, Tolcher Anthony W, Thompson John A, El-Khoueiry Anthony B, Vandross Andrae L, Kummar Shivaani, Shepard Dale R, LeDuke Kim, Sheehan Lisa, Alland Leila, Haque Arshad, Jalota Deepika, Fellous Marc, Schram Alison M
Abstract excerpt
BACKGROUND: Rezatapopt is an investigational, first-in-class, oral, selective p53 reactivator that specifically binds to Y220C-mutated p53, which stabilizes p53 in its wild-type conformation and restores its functionality. METHODS: In this phase 1, single-group, dose-escalation and dose-optimization study, we assigned heavily pretreated patients with locally advanced or metastatic solid tumors harboring a TP53...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.